Latest revenue
—
as of 2025-12-31
Latest net income
$-8.0M
as of 2025-12-31
Net margin
—
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ADIL is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $4.8M
- Enterprise value
- $-514.8K
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 1.29×
- Dividend yield
- 0.0%
- 52-wk high
- $3.95
- 52-wk low
- $0.15
- Beta
- —
- Shares out
- 2.1M
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Our investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder (“AUD”). AD04 was investigated in a Phase 3 clinical trial, designated the ONWARD trial, for the potential treatment of AUD in subjects with certain target genotypes, which were identified using our companion diagnostic genetic test. Based on our analysis of the subgroup data from the ONWARD trial, we are now focused on completing the clinical development program for AD04 in the…
AI summary unavailable — showing raw filing excerpt
Generated from ADIL's filing dated 2026-03-05
Key risks
Item 1A. Risk Factors. Investing in our securities involves a high degree of risk. In addition to the risks related to our business set forth in this Annual Report on Form 10-K and the other information included and incorporated by reference in this Annual Report on Form 10-K, you should carefully consider the risks described below before purchasing our securities. Additional risks, uncertainties and other factors not presently known to us or that we currently deem immaterial may also impair our business operations. Risks Relating to Our Company We have incurred net losses every year and quarter since our inception and anticipate that we will continue to incur net losses in the future. We…
AI summary unavailable — showing raw filing excerpt
Generated from ADIL's filing dated 2026-03-05
Profitability
Return on equity
-151.2%
53.2%Return on assets
-119.5%
54.3%Leverage
Debt / equity
0.26×
12.6%Long-term debt / equity
0.15×
41.0%Debt / assets
20.9%
9.9%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-2.0M | +9.3% | — |
Q4 2025 2025-12-31 | — | — | $-2.0M | +3.6% | — |
Q3 2025 2025-09-30 | — | — | $-1.8M | +18.2% | — |
Q2 2025 2025-06-30 | — | — | $-2.0M | +20.3% | — |
Q1 2025 2025-03-31 | — | — | $-2.2M | +65.6% | — |
Q4 2024 2024-12-31 | — | — | $-2.1M | — | — |
Q3 2024 2024-09-30 | — | — | $-2.2M | -58.3% | — |
Q2 2024 2024-06-30 | — | — | $-2.5M | -326.0% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ADIL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ADIL
Institutional value
$17.7K
Total shares held
9.9K
Distinct holders
10
-13 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD FIDUCIARY TRUST CO | 5.9K | $10.5K | — | New |
| 2 | Manchester Capital Management LLC | 1.9K | $3.4K | -46.2K (-96.0%) | Trimmed |
| 3 | BlackRock, Inc. | 1.1K | $2.0K | -26.7K (-96.0%) | Trimmed |
| 4 | UBS Group AG | 542 | $970 | -8.6K (-94.1%) | Trimmed |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 361 | $646 | — | New |
| 6 | SBI Securities Co., Ltd. | 47 | $84 | -1.1K (-95.9%) | Trimmed |
| 7 | Caitong International Asset Management Co., Ltd | 15 | $27 | — | New |
| 8 | WELLS FARGO & COMPANY/MN | 6 | $11 | -154 (-96.3%) | Trimmed |
| 9 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 4 | $7 | — | New |
| 10 | Abound Wealth Management | 1 | $2 | -26 (-96.3%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ADIL's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.